Exploring Next-Generation Businesses such as Automotive, Medical Devices and Biotechnology
First written in FY2016. 8 of 13 entries say "Restated". Latest entry: 2026-07-17.
1 other company's latest entry also says "Advanced".
- 2026-07-17AdvancedBusiness Alliances
「④将来的には、自動運転や LiDAR 向けの自動車部品や産業用ロボット等、光通信以外の分野に向けた製品開発も行ってまいります。」
次世代事業の探索対象について、光通信以外の分野として自動運転、LiDAR向け自動車部品、産業用ロボットを具体的に示した。 - FY2025-H1AdvancedAnnual report
「Name of acquired company: 株式会社エムジー Business activities: Manufacture and sale of automotive parts, stationery, medical components and other products」
The consolidation of 株式会社エムジー as a subsidiary added new products and industries, including medical components, to the Group’s business areas. - FY2023-Q3AdvancedAnnual report
「Sales of mold components for forming beverage containers and biochips for infectious disease testing also increased.」
The filing reports sales growth for biochips used in infectious disease testing, a product related to next-generation fields. - FY2022AdvancedAnnual report
「Started mass production of medical microfluidic devices made of resin with fine channels formed on the surface by repurposing precision mold technology.」
Regarding the exploration of next-generation businesses, the filing states that mass production has begun for medical microfluidic devices developed by repurposing precision mold technology for the medical field. - FY2021RestatedAnnual report
「It is also essential to use the cash generated by the earnings-base businesses and growth-driving businesses to identify and develop new next-generation businesses in industries expected to grow in the future, including automotive, medical devices and biotechnology.」
The company continues its policy of using cash generated by existing businesses for next-generation businesses in automotive, medical devices, biotechnology and other fields. - FY2020RestatedAnnual report
「It is also essential to use the cash generated by the earnings-base businesses and growth-driving businesses to identify and develop new next-generation businesses in industries expected to grow in the future, including automotive, medical devices and biotechnology.」
The company has reiterated its policy of using funds generated by its existing earnings-base and growth-driving businesses for next-generation businesses in automotive, medical devices, biotechnology and other fields. - FY2019-Q3RestatedAnnual report
「In addition, we focused on developing higher-value-added precision molded products for new markets such as medical care and biotechnology by applying precision mold, thin-wall molding and microtransfer technologies.」
The company continues to develop high-value-added precision molded products by applying its existing precision technologies to new markets such as medical care and biotechnology. - FY2019-Q2RestatedAnnual report
「In addition, we focused on developing higher-value-added precision molded products for new markets such as medical care and biotechnology by applying the precision mold, thin-wall molding and microtransfer technologies cultivated since the company’s founding.」
The company continues to develop next-generation businesses by applying its existing precision technologies to new markets such as medical care and biotechnology. - FY2019-Q1RestatedAnnual report
「In addition, we focused on developing higher-value-added precision molded products for new markets such as medical care and biotechnology by applying the precision mold, thin-wall molding and microtransfer technologies cultivated since the company’s founding.」
The company continues to develop next-generation businesses by applying precision mold, thin-wall molding and microtransfer technologies to new markets such as medical care and biotechnology. - FY2018-Q3RestatedAnnual report
「In addition, we focused on developing higher-value-added precision molded products for new markets such as medical care and biotechnology by applying the precision mold, thin-wall molding and microtransfer technologies cultivated since the company’s founding.」
The company continues to develop next-generation businesses by applying precision mold, thin-wall molding and microtransfer technologies to medical care, biotechnology and other fields. - FY2018-Q2RestatedAnnual report
「In addition, we worked to develop high-value-added precision molded products for new markets such as medical care and biotechnology by applying the precision mold, thin-wall molding and microtransfer technologies cultivated since the company’s founding.」
The company continues to develop high-value-added precision molded products for next-generation fields such as medical care and biotechnology by applying its existing technologies. - FY2017RestatedAnnual report
「It is also essential to use the cash generated by the earnings-base businesses and growth-driving businesses to identify and develop new next-generation businesses in industries expected to grow in the future, including automotive, medical devices and biotechnology.」
The company has reiterated its policy of using cash generated by existing businesses in next-generation fields such as automotive, medical devices and biotechnology. - FY2016First statedAnnual report
「It is also essential to use the cash generated by the earnings-base businesses and growth-driving businesses to identify and develop new next-generation businesses in industries expected to grow in the future, including automotive, medical devices and biotechnology.」
The company has indicated a policy of reallocating cash generated by existing businesses to new growth areas.